Evidence mapPaperPMID 40544252Full record

ReviewRespiratory research2025

Insights from precision-cut lung slices-investigating mechanisms and therapeutics for pulmonary hypertension.

William R Studley, Emma Lamanna, Claudia A Nold-Petry, Cheng Xue Qin, Jane E Bourke

Abstract readReview
In one paragraph

Review in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

William R StudleyBiomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0001-5020-6013
Emma LamannaBiomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, Australia.
Claudia A Nold-PetryRitchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-7439-3834
Cheng Xue QinMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-2169-2686
Jane E BourkeBiomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, Australia. jane.bourke@monash.edu.ORCID http://orcid.org/0000-0001-7314-9234

Funding

National Health and Medical Research Council 2033196National Health and Medical Research Council 2039688National Heart Foundation of Australia 102787
6 · The paper itself

Abstract

Precision-cut lung slices (PCLS) are gaining traction as a versatile ex vivo tool to study mechanisms and treatments for lung diseases. This preparation, in which the major structural elements of the native lung are preserved, bridges the gap between cell and in vivo models allowing researchers to assess integrated functional responses including smooth muscle reactivity, inflammation and tissue remodelling. To date, the application of PCLS to study outcomes relevant to diseases affecting the pulmonary vasculature, such as pulmonary hypertension, is relatively limited compared to those focussed on chronic airway or interstitial lung diseases. This review explores the specific technical requirements for the preparation of PCLS with viable, patent pulmonary arteries, and their application for investigation of mechanisms and treatments related to pulmonary hypertension. Studies characterising vascular responses to contractile agonists in PCLS, particularly in the context of disease-relevant stimuli and models are described, as well as the use of PCLS for the identification of novel vasodilators. This article also outlines current research to prolong PCLS viability and provides directions for future PCLS studies to investigate inflammation and vascular remodelling, with a view to identify therapeutics that address the current limitations of dilator-only treatment of pulmonary hypertension. Overall, the review highlights the importance of PCLS for mechanistic studies and drug development. While PCLS are currently underutilised in the context of pulmonary hypertension, the evidence provided here of the multifaceted functional outcomes that can be investigated using PCLS supports their wider application for understanding disease pathophysiology and validating novel therapeutics.

Indexed as

Hypertension, PulmonaryLungAnimalsHumansPulmonary ArteryVascular RemodelingVasodilator AgentsVasodilator AgentsFibrosisInflammationPrecision cut lung slicesPulmonary hypertensionReactivityVasoconstrictorVasodilator

Identifiers

PMID40544252
PMCPMC12181927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.